Today's Change
+0%
AI Sentiment
62%
Sector AnalysisLive data
Materials Sector Outlook
The Materials sector is up 0% today with bullish sentiment across 2 recent news articles.
Bullish Factors
- No strong bullish signals detected
Risk Factors
- No strong bearish signals detected
Stocks in Materials
0 stocks| Symbol | Company | Change |
|---|
Materials News
928 articlesGlobeNewswire Inc.67d ago
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
The Motley Fool67d ago
Retail Sentiment on TMC Has Flipped Bullish Even as the Stock Sits 17% Down This Year
GlobeNewswire Inc.67d ago
Theriva™ Biologics anuncia la próxima presentación de datos adicionales del ensayo clínico VIRAGE de Fase 2b del VCN-01 para el cáncer de páncreas metastásico en la Reunión Anual de la AACR de 2026
The Motley Fool67d ago
Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares?
The Motley Fool67d ago
The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock?
GlobeNewswire Inc.67d ago
CORT DEADLINE ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class Action – CORT
GlobeNewswire Inc.67d ago
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLNO
GlobeNewswire Inc.68d ago
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
GlobeNewswire Inc.68d ago
Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities
GlobeNewswire Inc.68d ago
Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform
Market Sentiment
Bullish
62% Sentiment Score
Sector Stats
Total Stocks0
News Today2
Avg Volume0
AI SentimentBullish